FIG. 1.

Multivariable-adjusted relative risk of VTE according to joint categories of oral hormone therapy use and GRS. All analyses were adjusted for age (in months), BMI (continuous and indicator for missing; excluded for the stratified analysis for BMI groups), physical activity (continuous and indicator for missing), alcohol use (continuous and indicator for missing), smoking, (never, former, or current), current aspirin use (yes or no), parity (none, one, or more than one), prevalent diabetes, prevalent hypertension, prevalent hypercholesterolemia, prevalent MI/angina, prevalent cancer, and hysterectomy (yes or no). Dots indicate the adjusted relative risk (RR) of VTE by joint categories of oral hormone therapy use and GRS. In each HT category, the red dot refers to the RR of women in the low GRS group, the blue dot refers to the RR of women in the intermediate GRS group, and the purple dot refers to the RR of women in the high GRS group. The black line including the dot shows the 95% CI of the RR. The reference group (never user) was used for comparing to all the subgroups of oral HT use status, type of oral HT use, duration of HT use, and HT initiation. BMI, body mass index; CI, confidence interval; GRS, genetic risk score; HT, hormone therapy; MI, myocardial infarction; VTE, venous thromboembolism.

VTE, venous thromboembolism; GRS, genetic risk score; HT, hormone therapy; CI, confidence interval.